Drug profile · INN
adenovirus-mediated herpes simplex virus-thymidine kinase gene
CEREPRO
adenovirus-mediated herpes simplex virus-thymidine kinase gene (CEREPRO) is an FDA-listed pharmaceutical active ingredient. Associated with Ark Therapeutics.
EMA: application withdrawn
Patents linked 1
Pipeline programs 1
News articles 0
Drug details — adenovirus-mediated herpes simplex virus-thymidine kinase gene
- Class
- —
- Route
- —
- Patents
- 1
- Programs
- 1
- Data quality
- 0.89
Quick answer
adenovirus-mediated herpes simplex virus-thymidine kinase gene (CEREPRO) is an FDA-listed pharmaceutical active ingredient. Associated with Ark Therapeutics.
Key facts
INN adenovirus-mediated herpes simplex virus-thymidine kinase gene
Brand CEREPRO
Originator Ark Therapeutics
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | application withdrawn | — |
Pipeline programs
Related patents
Frequently asked questions
What is adenovirus-mediated herpes simplex virus-thymidine kinase gene?
adenovirus-mediated herpes simplex virus-thymidine kinase gene (CEREPRO) is an FDA-listed pharmaceutical active ingredient. Associated with Ark Therapeutics.
What is the brand name for adenovirus-mediated herpes simplex virus-thymidine kinase gene?
CEREPRO is a marketed brand name for adenovirus-mediated herpes simplex virus-thymidine kinase gene. Check FDA Drugs@FDA for the current US label holder and prescribing information.